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ARTÍCULO ORIGINAL
Plasmodium falciparum: high frequency of pfcrt point mutations
and emergence of new mutant haplotypes in Colombia
Eliana Restrepo, Jaime Carmona-Fonseca, Amanda Maestre
Grupo Salud y Comunidad, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
Introduction. Studies on the molecular epidemiology of antimalarial resistance constitute a
useful tool to understand the events underlying treatment failure and resistance in falciparum
malaria in Colombia. Several authors have reported on the efficacy of some molecular markers
to predict drug resistance in Plasmodium falciparum. The P. falciparum pfcrt gene has been
widely characterized in this context.
Objective. The frequency of pfcrt gene mutations in P. falciparum were associated with treatment
failure to the antimalarials chloroquine, mefloquine, amodiaquine and sulfadoxine/
pyrimethamine.
Materials and methods. A representative sample of 172 patients with non-complicated
falciparum malaria was selected from two highly malaria-endemic areas of northeastern
Colombia, the Turbo and Bajo Cauca regions. These patients were assessed for treatment
response together with the status of codons 72, 74, 75 and 76 in the pfcrt gene using a PCR-
RFLP approach.
Results. A high frequency of treatment failure to chloroquine (82%) and to amodiaquine (29%)
was confirmed, whereas mefloquine and combined therapy remained effective. The presence
of the T76 mutation in pfcrt was confirmed in all samples. The most common haplotype was
CMNT (67%).
Conclusions. No significant association was confirmed between specific haplotypes and the
treatment response in any of the treatment groups. Two haplotypes, SMET and SMNT, were
reported for the first time in Colombia. Twelve percent of the samples carried both mixed mutant
and wild-type alleles.
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Alta frecuencia de mutaciones puntuales en pfcrt de Plasmodium falciparum y emergencia
de nuevos haplotipos mutantes en Colombia
Introducción. Los estudios en epidemiología molecular de resistencia a antipalúdicos
constituyen una herramienta útil para comprender eventos involucrados en la falla al tratamiento
y la resistencia en paludismo por Plasmodium falciparum en Colombia. Diversos autores han
informado sobre la eficacia de algunos marcadores moleculares para predecir resistencia a
fármacos en P. falciparum y el gen pfcrt ha sido ampliamente caracterizado en este contexto.
Objetivo. Estudiar la frecuencia de mutaciones en el gen pfcrt de P. falciparum y su asociación
con falla al tratamiento con cloroquina, mefloquina, amodiaquina y sulfadoxina/pirimetamina,
en dos regiones muy endémicas para paludismo del noroeste de Colombia: Turbo y Bajo
Cauca.
Materiales y métodos. Una muestra representativa de pacientes con paludismo por P. falciparum
no complicado fue seleccionada de cada localidad para la evaluación de la respuesta al
tratamiento y la determinación del estado de los codones 72, 74, 75 y 76 de pfcrt, usando una
aproximación basada en PCR-RFLP.
Resultados. Se confirmó una alta frecuencia de falla al tratamiento con cloroquina (82%) y
amodiaquina (29%), mientras que la mefloquina y la terapia combinada fueron eficaces para
eliminar la infección. La presencia de la mutación T76 en pfcrt fue confirmada en todas las 172
muestras; el haplotipo más común fue CMNT (67%).
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Conclusiones. No se observó asociación significativa entre un haplotipo particular y la
respuesta al tratamiento en cualquiera de los grupos. Se reporta por primera vez en Colombia
la presencia de dos haplotipos, SMET y SMNT; se encontraron alelos mutantes y silvestres
simultáneamente en 12% de las muestras.
Palabras clave: Plasmodium falciparum, malaria, antimaláricos, cloroquina, Colombia,
mutación.
Plasmodium falciparum malaria affects approxi-
mately 300 million people worldwide and claims
an estimated 1.5 million lives every year. Without
a fully protective vaccine, chemotherapy is the
only effective treatment of the disease. In many
parts of the world, the P. falciparum parasite has
become resistant to most drugs (1,2), undermin-
ing the efforts for malaria control.
Traditionally, chloroquine (CQ) has been the drug
of choice for the treatment of malaria. However,
CQ-resistant parasites are now present in most
areas where malaria is endemic (3). In Colombia,
treatment failure to CQ was detected as early as
1960, and the number of resistant cases contin-
ued to rise. Consequently, the decline in the effi-
cacy of CQ as monotherapy led to the use of com-
bined therapy with other antimalarials, such as
antifolates; however, parasite resistance to these
regimens was also appearing. Studies on efficacy
of amodiaquine (AQ) have discovered associated
parasite mutations, such as the CQ resistance
transporter (pfcrt) gene.  They concluded that se-
lection by drugs on the parasite population was
the probable explanation for the presence of mu-
tations in  parasites of recurrent cases after treat-
ment with the antimalarial (4,5). In the case of
mefloquine (MQ), the evidence suggested an as-
sociation between mutations on the codon 76 of
the pfcrt gene and reduced susceptibility to MQ
(6,7).
Currently, the national Colombian health authori-
ties are monitoring the efficacy of alternative drugs,
either administered alone or as combined therapy,
to develop policy recommendations for adequate
treatment regimens. Studies on the molecular
epidemiology of antimalarial resistance constitute
a useful tool to understand the events underlying
treatment failure and resistance in falciparum
malaria in Colombia.
Certain molecular markers predict drug resistance
in P. falciparum. CQ resistance is conferred by
mutations in the pfcrt gene; this gene encodes a
putative transporter localized in the digestive vacu-
ole (8,9). The substitution of lysine (K) for threo-
nine (T) at amino acid 76 (K76T) in the pfcrt pro-
tein appears to be a primary genetic mechanism
conferring resistance to CQ (10). This codon has
been considered as a highly reliable genetic marker
for the monitoring CQ resistance (11). In African
or Southeast Asian isolates, the K76T mutation
in pfcrt does not occur alone, but is accompanied
by mutations in other codons (74, 75, 220, 271,
326, 356 and 371). South American isolates may
carry, besides K76T, mutations in codons 72, 74,
75, and 220 (12,13).
In the current study, the frequency of mutations
in the pfcrt gene was determined.  The presence
of each mutation was associated with treatment
failure to the antimalarials CQ, MQ, AQ as
monotherapy  as well as AQ plus sulfadoxine/py-
rimethamine (SP) therapy.
Materials and methods
Patients and blood samples
The study was conducted from 2002 to 2004 in
patients living in three counties: Turbo (8°5’42"
N, 76°44’123" W), El Bagre (7°35’25" N,
74°48’27" W), Zaragoza (7°29'24"N, 74°51'35"W)
in two regions of northwestern Colombia where
malaria is highly endemic: Urabá and Bajo Cauca
which are mainly inhabited by descendants from
African and indigenous ancestors, as well as
mixed indigenous and Spanish ancestry. Subjects
were residents in townships located within a 40
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km radius from the urban area of the county. The
economy of Bajo Cauca is based on gold mining,
whereas Urabá is a banana-producing region. Both
regions have high migration rates and malaria
transmission is perennial and unstable with mean
annual parasites indices of 19.6 per 1,000 in Turbo
and 37.4 per 1,000 in El Bagre  (data of 2002-
2004).  Because the research reported herein was
conducted before 2007, it was not recorded in the
WHO and ICMJE (International Committee of
Medical Journal Editors) databases for clinical
studies.
The reference population consisted of patients
aged ≥1 year, with a history of fever and symp-
toms compatible with malaria. A single infection
with P. falciparum was confirmed by thick smear.
The patients had no treatment with CQ, SP or AQ
treatment within the past 3 days and no history of
MQ intake during the previous 4 weeks. The pa-
tients were visitors at the malaria diagnosis clinic
at a local hospital. The minimum required sample
size (n) was calculated by the following equation:
n=NZ2p(1-p)/(Ne2)+{Z2p(1-p)}, where N was the
number of P. falciparum malaria cases in each
locality, Z was the confidence level (for 0.95, Z =
1.96), p was the proportion or probability of P.
falciparum genetic variation in the region, 1-p was
the probability that the genetic variation was not
real, and e was the sample error (13.3%).  Based
on this calculation, a minimum sample of 50 pa-
tients was chosen from each community.
Patients were included in the study if they were
males or non-pregnant females (confirmed by a
rapid pregnancy test), living at their normal resi-
dence in the rural or urban zone of their munici-
pality. The inclusion criteria were the following:
(a) to have non-complicated malaria (confirmed
by clinical and microscopy findings); (b) to harbor
between 250 and 50,000 asexual parasites/ml; (c)
to be free of a concomitant disease (based on a
clinical interview and examination by the team’s
physician); (d) to voluntarily participate in the
study; and (e) to commit to attendance at the fol-
low-up examinations. The exclusion criteria were
the following: (a)  evidence of severe malaria or
other disease; (b) indication of adverse effect of
antimalarial drugs or other medicationss; or (c)
failure to attend any of the first three follow-up
examinations (days 1, 2, 3). Evidence of treat-
ment failure to due to antimalarial therapy resulted
in withdrawal of the patient from the study.  Rec-
ommendations for a rescue treatment was formu-
lated according to the guidelines for malaria treat-
ment provided by the Colombian Ministry of Health
(i.e., quinine and clyndamycin treatment).
Each patient (or their parents) gave fully informed
written consent. Ethical clearance was granted by
the Ethics Committee of the Centro de
Investigaciones Medicas, Facultad de Medicina,
Universidad de Antioquia (Medellin, Colombia).
Patients were randomly assigned to one of the
following treatments: (1) chloroquine, 25 mg/kg
body weight for 3 days; (2) amodiaquine, 25 mg/
kg body weight for 3 days; (3) mefloquine, 15 mg/
kg body weight for 1 day; or( 4) amodiaquine, 25
mg/kg body weight for 3 days, plus a single dose
of sulfadoxine/pyrimethamine 25/1 mg/kg. All pa-
tients were administered treatment at the local
malaria clinic; the follow up period was at least 21
days. Treatment response was assessed accord-
ing to the 1998 WHO protocol for in vivo efficacy
studies of antimalarial drugs, and the treatment
outcomes were classified either as an adequate
response to treatment or as treatment failure (14).
Peripheral blood parasitaemia was determined from
fingerprick blood. Giemsa-stained thick/thin blood
films were examined microscopically to identify
the Plasmodium species, parasite density, and
schizontaemia. Parasite density was measured
by counting the number of asexual parasites per
200 leukocytes, based on a mean count of 8,000
leukocytes per microliter of blood. A slide was
considered negative after examination of
microscopic fields corresponding to at least 500
leukocytes.
Molecular analyses
Blood for molecular analyses was taken on day 0
and on the day of treatment failure. Whole blood
was collected on Whatman 3M filter paper and
stored at -20° C until DNA extraction with
Chelex®, according to standard procedures (15).
DNA templates were stored at -20° C until use.
Polymorphisms of codons 72, 74, 75 and 76 of
the pfcrt gene were analysed by nested PCR as
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described by Djimde et al. (11). The product size
was assessed by polyacrylamide (13%) gel elec-
trophoresis. The results were interpreted as fol-
lows: pfcrt allele 72 (C72 wild, S72 mutant); 74
(M74 wild, I74 mutant); 75 (N75 wild, E75 mu-
tant); and 76 (K76 wild, T76 mutant). Controls in-
cluded the reference P. falciparum strains 3D7,
Dd2 and Hb3.
Statistical analysis
The data obtained were processed using EpiInfo
6.04. The frequency of each variable was calcu-
lated, and the association between treatment re-
sponse and the presence of mutant alleles was
tested by j² test. The level of significance was set
at p<0.05.
Results
In vivo evaluation of the efficacy of
antimalarials
In total, 172 patients were included in the study—
91 from Turbo and 81 from Bajo Cauca (Table 1).
The geometric mean parasite density was 38,858
asexual parasites/ml. A high number of patients
evidenced signs of severe malaria after being al-
located to groups 1 or 2. In such cases, patints
were excluded from the study and offered antima-
larial treatment for severe malaria.
The overall proportion of treatment failure was
30%, with CQ showing the highest proportion
(82%). The distribution of patients according to
the respective treatment and the rates of success
are shown in Table 1.
pfcrt genotypes
Genetic characterization of pfcrt was performed
on 153 blood samples collected on the day before
treatment and on 19 post-treatment samples from
patients who presented with treatment failure. The
19 post-treatment failures were distributed among
the treatment groups as follows: 6 in the CQ group,
8 in AQ , 4 in MQ and 1 in AQ-SP. The key codons
of the pfcrt gene were analyzed in 172 DNA
samples.
The mutant allele T76 in the pfcrt gene was found
in all samples (100%). Infection with a single hap-
lotype was observed in 88% of the samples;  in-
fections with two haplotypes was detected in 12%
of the samples. No significant association was
detected between a particular haplotype and the
treatment response in any of the groups. Simi-
larly, selection for a specific haplotype with any
of the antimalarials was not observed (Table 2).
The most common haplotype was CMNT, observed
in 67% of the samples. The distribution of the
haplotype patterns is shown in table 2. No signifi-
cant association between a particular haplotype
and the origin of the sample was observed.
Discussion
In Colombia, the recommended treatment regimen
for uncomplicated falciparum malaria has been AQ
(25 mg/kg in 3 days) and SP (25 mg/kg–1 mg/kg.
This scheme was used throughout the country fpr
the past decade, until 2006. However, the AQ-SP
regime had been adopted much earlier in the Turbo-
Table 1. Distribution of patients according to treatment group, place of residence (locality) and percentages of patients
with treatment failure regardless of the locality.
Treatment Locality Number of patients Number of patients Patients with
recruited with treatment failure  treatment failure (%)
Chloroquine Bajo Cauca 9 7 82
Turbo 8 7
Amodiaquine Bajo Cauca 13 5 29
Turbo 21 5
Mefloquine Bajo Cauca 33 3 5
Turbo 40 1
Amodiaquine- Bajo Cauca 26 1 2
sulfadoxine- Turbo 22 0
pyrimethamine
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Table 2. Distribution of haplotypes of pfcrt codons 72, 74, 75 and 76 according to treatment group and treatment response
in 153 isolates from day 0 (D.0) and in 19 isolates from day of failure (D.F.). CQ, chloroquine; AQ, amodiaquine; MQ,
mefloquine; SP, sulfadoxine/pyrimethamine.
Allele Haplotype Percentage (n) CQ (n) AQ (n) MQ (n) AQ+S-P (n)
D.0/D.F. D.0/D.F. D.0/D.F. D.0/D.F.
Wild C M N K 0% (0) 0/0 0/0 0/0 0/0
Mutant 1 C M N T 67% (115) 9/5 8/8 41/3 40/1
Mutant 2 C M E T 9% (16) 0/0 0/0 14/1 1/0
Mutant 3 S M N/E T 9% (15) 0/0 0/0 9/0 6/0
Mutant 4 S M N T 12% (20) 11/1 3/0 5/0 0/0
Mutant 5 C/S M N T 3% (6) 1/0 1/0 2/0 2/0
TOTAL 100% (172) 21/6 12/8 71/4 49/1
Bajo Cauca region, because of clinical evidence
confirming an increasing treatment failure by that
time (16).In addition, other antimalarials, such as
mefloquine and quinine, are available for resistant
or complicated malaria. Furthermore, self medication
with halofantrine is known to occur in some localities.
At present, artemisinin derivates are included as
first-line medication. The current study confirmed
the high frequency of treatment failure to all the
antimalarials historically used for monotherapy in
the country (CQ, AQ). However, high efficacy of
treatment with MQ and AQ-SP was observed.
The purpose of the present study was to
characterize the treatment failure phenomenon at
the molecular level by identification of mutations
in the pfcrt gene. The presence of pfcrt T76 was
confirmed in each of the 172 samples studied,
indicating complete selection of this mutation by
the antimalarial drugs and explaining the high
treatment failure rates for CQ and, probably, to AQ.
This concurs with reports of the distribution of this
gene in other geographic regions worldwide
(1,17,18).
In addition to pfcrt, another extensively investigated
gene is the P. falciparum multiple drug resistance
1 (pfmdr1), encoding a P-glycoprotein 1 (Pgh-1).
Mutations at the 86, 184, 1034, 1042, and 1246
positions have been strongly linked to CQ-resistance
in vitro (19-23) and in vivo (24,25). These
mutations of the pfmdr1 gene were thought to play
a role in the  enhancement of resistance levels in
CQ-resistant parasites (26). However, recently Mita
et al. (27) observed a significant non-random
association between the pfcrt T76 and pfmdr1 Y86
alleles. They concluded that under CQ selection
pressure the Y86 mutation in pfmdr1 may augment
the level of CQ resistance in the T76 alleles.
Analysis by PCR-RFLP of the pfmdr1 gene on the
samples reported here confirmed the presence of
pfmdr1 N86 (wild) in 97% of the samples, and the
1246Y mutant allele was detected on 92% of them
(28). The significance of these associations
remains to be determined.
Previous studies have reported the reversal of the
wild type (K76) genotype after cessation of CQ
use (29,30). Although the current study was not
aimed at exploring this phenomenon, the
persistence of the T76 mutant phenotype was
detected in a geographic region where use of CQ
for falciparum malaria (but not vivax malaria) was
abolished 21 years ago. Because vivax malaria
accounts for a high proportion of the total malaria
cases and because CQ remains for use in vivax
treatment, undoubtedly, some falciparum parasites
continue be exposed to CQ and pressure selection
for mutant alleles continues to be applied in the
Turbo-Bajo Cauca region. This exposure will likely
occur in malaria patients who had been treated
previously for vivax malaria and shortly thereafter
undergo treatment for a new falciparum infection.
Possibly the previous treatment had occurred in
a case of undetected mixed malaria infections or
alternatively, low CQ plasma levels remain frp,
the previous treatment. The significance of this
hypothesis in explaining the persistence of the
T76 mutant phenotype remains to be explored.
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The most common pfcrt haplotype was CMNT.
This confirmed previous reports of the presence
of codon 76 (31), but contrasts with others that
reported on samples from the Colombian Pacific
Coast (32).The SMNT haplotype was the second
in frequency (24%) and was observed in
combination with the SMET haplotype in 9% of
the samples. SMNT has been reported in Brazil
and Peru (33); however, the SMET mutant
haplotype reported herein has never been reported
previously in South America. The presence of
African, South American, Southeast Asian, and
of the SMET and SMNT pfcrt haplotypes are
reported here in Colombia for the first time. The
questions remains as to whether these five
haplotypes have evolved by sequential mutations
of the pfcrt gene, or whether parasites with these
haplotypes have been imported into the region.
The latter alternative is a feasible explanation for
the presence of SMNT in Colombia, since this
haplotype is widely distributed throughout the
continent. E75 (as in SMET) is very common in
Asia and has been reported in Brazil and Peru
(34).  Its presence in Colombia may have resulted
from recombination of several parasite populations
carrying SMNT or CMET. Analysis directed toward
haplotype origin in the genomes of P. falciparum
samples remains to be undertaken.
Mixed mutant and wild-type alleles were detected
in 12% of the 176 samples. In addition, polyclonal
infections were present, at least for the pfcrt
codon,, in all samples obtained on the day of treat-
ment failure. This was possibly the consequence
of a clearance of susceptible phenotypes. How-
ever, the effect of drug pressure on selecting
mutant alleles, at least for codons 72 and 75, was
not statistically confirmed. Further analysis of other
genes such as MSP-1, MSP-2 and GLURP is
necessary to better address the issue of single or
polyclonal infection.
In conclusion, the treatment of P. falciparum
patients with either CQ or AQ as monotherapy, is
not effective in the Turbo-Bajo Cauca regions,
whereas MQ and the combined AQ-SP therapy
remain effective in clearing the infection. The most
common pfcrt haplotype was CMNT (67%),
followed in frequency by the SMNT haplotype
(12%). However the SMNT haplotype was detected
in association with a second haplotype in an
additional 12% of the samples. No significant
association was confirmed between a particular
haplotype and the treatment response in any of
the treatment groups, or the place of residence of
the patient. With a greater sample size, positive
relationships may yet be detected.  Alternatively,
existing relationships may have been swamped
by the overwhelming presence of the CMNT
haplotype.
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